Domestic infertility rate increases, assisted reproductive cross-border medical treatment
As of 2012, the number of infertility in China has risen to 40 million, accounting for 12.5% ​​of the childbearing population. In 1995, China’s infertility rate was only about 3%. From 2012 to 2016, the number of infertility in China quickly rose from 40 million to 50 million, and the overall The rate of pregnancy infertility has risen to around 15%. At present, China's high infertility rate provides a basis for the development of the domestic assisted reproductive industry.
However, China's assisted reproductive approval has been stricter. In September 2016, the National Health and Family Planning Commission's notice on simplifying the inspection procedures for birth certificates in the treatment of human assisted reproductive technology alleviated this situation to some extent. Compared with overseas assisted reproductive medicine, the domestic assisted reproductive industry still has disadvantages such as strict approval, backward technology, and insufficient professional institutions. In recent years, assisted reproductive cross-border medical care has become more and more popular among Chinese people.
Figure 1: Analysis of the advantages of assisted reproductive cross-border medical industry
Source: Prospective Industry Research Institute
The development status of the assisted reproductive cross-border medical industry, the accelerated growth of the assisted reproductive cross-border medical cycle
As of 2016, the number of assisted reproductive cases in 432 assisted reproductive institutions in China is about 700,000. In view of the increasing trend of infertility in China, the current domestic gap is about 800,000 cases. According to the statistics of the Prospective Industry Research Institute, in 2016, the domestic Assisted Reproductive Cross-border Medical Market was about 7.4 billion yuan. It is estimated that in 2017, the Assisted Reproductive Cross-border Medical Market will exceed 9 billion yuan.
Chart 2: China's Assisted Reproductive Cross-border Medical Market Size in 2014-2017 (Unit: 100 million yuan)
Source: Prospective Industry Research Institute
Tetanus Toxoid Vaccine,Toxoid Vaccine,Hep B Immune Globulin,Immunoglobulin Injections
FOSHAN PHARMA CO., LTD. , https://www.fospharma.com